E N D
2. Primary ObjectiveALLHAT - LLT
4. Secondary Outcomes
CHD
Cause-specific mortality
Total and site-specific cancers
5. Major Subgroups (a priori) Age 65+
Women
African-Americans
Type 2 Diabetes
6. Major Subgroups(post hoc) CHD at Baseline
No CHD and
LDL-C = 130 mg/dL
No CHD and
LDL-C < 130 mg/dL
7. Eligibility Criteria
9. Exclusion Criteria Continuing use of prescribed lipid-lowering agents
Contraindications to statins
Secondary cause of elevated serum cholesterol
ALT > 2 times ULN
10. Clinical Sites in LLT 513 clinical sites
United States, Canada, Puerto Rico, US Virgin Islands
VA, private & group general medicine practices, community health centers, HMOs, specialty practices
Variety of research experience
12. Vital Statusat Closeout 8776 (84.8%) known alive
1272 (12.3%) confirmed deaths
55 ( 0.5%) confirmation of death pending
206 ( 2.0%) lost
46 ( 0.4%) refused
27. Meta-Analysis of Large Long-Term Statin Trialsand Impact of ALLHAT - LLT
30. ConclusionsALLHAT - LLT